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The objective of this study was to subjectively evaluate the harvest of two areas of 
adipose collection and three areas of bone marrow collection as potential sites for clinical 
harvest of adipose stromal vascular fraction (SVF) and bone marrow concentrate for 
clinical use by quantifying the amount of tissue harvested, subjective ease of harvest, 
the variation of each site, and determining the cell surface marker characteristics using 
commercially available antibodies. Bone marrow and adipose tissue samples were col-
lected from 10 adult mixed breed dogs. Adipose tissue was collected from the caudal 
scapular region and falciform fat ligament. Bone marrow aspirates were collected from 
the ilium, humerus, and tibia. Tissues were weighed (adipose) or measured by volume 
(bone marrow), processed to isolate the SVF or bone marrow concentrate, and flow 
cytometry was performed to quantitate the percentage of cells that were CD90, CD44 
positive, and CD45 negative. Sites and tissue types were compared using matched pairs 
t-test. Subjectively subcutaneous fat collection was the most difficult and large amounts 
of tissue dissection were necessary. Additionally the subcutaneous area yielded less 
than the goal amount of tissue. The bone marrow harvest ranged from 10 to 27.5 ml. 
Adipose tissue had the highest concentration of cells with CD90+, CD44+, and CD45− 
markers (P < 0.05), and bone marrow had the highest total number of these cells at 
harvest (P < 0.05). Variation was high for all sites, but the adipose collection yielded 
more consistent results. These results describe the relative cellular components in the 
SVF of adipose tissue and bone marrow as defined by the biomarkers chosen. Although 
bone marrow yielded higher absolute cell numbers on average, adipose tissue yielded 
more consistent results. Fat from the falciform ligament was easily obtained with less 
dissection and therefore created less perceived relative patient trauma.
Keywords: canine, adipose, bone marrow, stromal vascular fraction, mesenchymal stem cell
Abbreviations: aMSCs, adipose-derived mesenchymal stem cells; bMSCs, bone marrow-derived stem cells; DMEM, Dulbecco’s 
Modified Eagle’s Medium; FACS, fluorescent-activated cell sorting; MSCs, mesenchymal stem cells; PEST, penicillin/
streptomycin.
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inTrODUcTiOn
Mesenchymal stem cells (MSCs) are a population of cells, which 
have the ability for self-renewal, long-term viability, and multilin-
eage potential (1). MSCs have been shown to have the ability to 
regenerate into bone, cartilage, muscle, tendon, ligament, adipose, 
and stroma (2). There has been increasing interest in the clinical 
use of MSCs in both human and animal research. MSCs can be 
isolated from multiple tissues and delivered in multiple forms. 
After harvest, cells may be cultured creating a more homogenous 
and biomarkers change over time and may be dependent on 
culture conditions (3–5).
However, in small animal veterinary medicine, cultured cells 
have been less commonly used. Instead, a heterogeneous cell popu-
lation is concentrated from bone marrow aspirates or adipose tissue 
harvest prior to the injection back into the animal. An adipose-
derived population of cells called stromal vascular fraction (SVF) 
is created by digesting the fat and concentrating the remaining 
cells. These mixed cell populations and some MSC-concentrated 
preparations have mainly been applied to enhance tendon and liga-
ment repair, fracture healing and to manage joint diseases (2, 6–11).
The use of stem cells has gained popularity in veterinary clinics 
(2, 12) in many forms and now extends beyond orthopedics, to 
manage other inflammatory conditions, such as inflammatory 
bowel disease and acute thoracolumbar disk disease (13, 14).
In spite of this expansion, the SVF has not been characterized 
in dogs compared to humans or bone marrow concentrate (6, 
15). The additional elements of preparations that have not been 
cultured likely include smooth muscle cells, pericytes, fibroblasts, 
endothelial cells, hematopoietic stem cells, leukocytes, and 
endothelial progenitor cells (4, 16). Autologous SVFs have been 
used commercially since 2003 in veterinary medicine without the 
knowledge of the cellular make-up of the treatment (2, 8). The 
justification of their clinical use was based on the assumption that 
the SVF in dogs would be similar to that in man.
Variation among tissue types and/or sites used for cell harvest 
may make one tissue or site more clinically advantageous. The 
benefits of collection of adipose tissue for cell isolation include 
more abundant tissue, accessibility, and potentially higher MSC 
populations (17). It is believed that adipose tissue has minimal 
donor site morbidity as compared with bone marrow harvesting 
(18). Adipose vascular fraction provides a rich source of adipose-
derived mesenchymal stem cells (aMSCs) with one study finding 
500 times more stem cells in adipose compared to bone marrow 
(19, 20). The frequency of aMSCs in humans is 300 times the MSC 
frequency in bone marrow, which is only 0.01–0.001% (2, 20). 
However, this may not be true in dogs.
Location of harvest may also affect the number of MSCs 
harvested. Studies have been performed in human research as 
well as other animal species to determine the collection site with 
the highest yield of MSCs, but this has not been performed in the 
canine despite the use of aMSCs clinically. A human study evalu-
ating the effect of tissue-harvesting site on aMSC yield showed 
that proliferation or differentiation capacities was not dependent 
on the tissue-harvesting site, but yield depended on the site (21).
The objective of this study was twofold: (1) to subjectively 
evaluate and compare the difficulty of harvest of two areas of 
adipose collection and three areas of bone marrow collection. 
(2) To determine and compare the tissue yield, cellular yield, and 
variation of adipose SVF and bone marrow concentrate harvest 
for each site. First, we hypothesized that adipose tissue would 
be physically easier to harvest in adequate quantities than bone 
marrow. Second, we hypothesized that nucleated cell count would 
be higher in the adipose SVF when expressed as a percentage 
of tissue harvested. Third, we hypothesized that the falciform fat 
would yield a higher percentage of potential MSCs as defined by 
CD90+, CD44+, and CD45− biomarkers.
MaTerials anD MeThODs
harvest
The samples were harvested from five sites antemortem with 
approval from the University of Minnesota Institutional Animal 
Care and Use Committee (approval number 0803A29646). Ten 
adult and mixed breed dogs being euthanized for other purposes 
were used for this study. Anesthesia was induced with propofol, 
the dogs were intubated, and maintained on isoflurane for tissue 
harvest. Dogs were humanely euthanized prior to anesthetic 
recovery with pentobarbital. Dogs were weighed and body condi-
tion score was assessed on a scale of 1–9. Bone marrow aspirates 
were aseptically harvested from the wing of the ilium, proximal 
medial tibia, and proximal humerus using an 11-gage Jamshedi 
needle similar to standard bone biopsy technique. The bone was 
palpated; a small incision was made into the skin and subcutane-
ous tissues. Once the needle was inserted, a 35-ml heparinized 
syringe (1000 IU/ml of blood) was used to aspirate bone marrow 
and blood.
Adipose tissue was aseptically harvested from the subcutane-
ous fat caudal to the scapula and the falciform fat ligament using 
standard surgical technique. The goal was to harvest 30 g at each 
site of adipose tissue collection. Caudal to the scapula, the skin 
was incised, and sharp and blunt dissection was used to remove 
the fat. For falciform fat harvest, a midline cranial abdominal 
incision was made and the falciform fat was collected with sharp 
dissection.
All fat samples were collected in 50  ml conical tubes and 
weighed. The adipose tissue was washed extensively with 
phosphate-buffered saline and minced. An equal volume of digest 
medium was added and shaken at 150 rpm at 37°C for 45 min. 
The digest medium was composed of Hank’s solution with 0.075% 
collagenase type 1, 1% bovine serum albumin, and 1% penicillin/
streptomycin (PEST) solution (22, 23). The resulting solution was 
centrifuged at 250 × g for 5 min and the supernatant discarded. 
The bone marrow was treated with red cell lysis buffer, centrifuged 
at 250 × g for 5 min, and the supernatant was discarded.
For both adipose and bone marrow, the pellet was resuspended 
in Dulbecco’s Modified Eagle’s Medium with F-12 (DMEM/F-12) 
and filtered sequentially using 100 μm and 40 μm nylon mesh 
to remove cellular debris. The remaining cells were washed, 
counted using Trypan blue to distinguish viable from dead 
cells, and frozen in two million cells per milliliter aliquots. The 
freezing medium consisted of DMEM with 50% FBS and 10% 
dimethyl sulfoxide.
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Flow cytometry
Prior to flow cytometry preparation, cells were thawed and placed 
in 10 ml of DMEM to dilute the dimethyl sulfoxide. The cells were 
collected by centrifugation at 400 × g for 5 min. Canine-specific 
or cross-reacting antibodies attached to fluorochromes [CD14 
(Pacific Blue), CD34 (rPE), CD44 (APC-Cy7), CD45 (Alexa 
Fluor® 647), and CD90 (PerCp-Cy5.5)] were purchased commer-
cially.1 The APC-Cy7 and PerCp-Cy5.5 fluors were conjugated 
to their respective antibodies according to the manufacturer’s 
directions.2 Attachment of fluorescently labeled antibodies was 
done according to the manufacturer’s directions (see text footnote 
“a”). In brief, cells were incubated with the antibodies for at least 
30 min at room temperature. Red cell lysis buffer was added, and 
samples were gently rocked in the dark for 10 min to eliminate 
the red cell population. After centrifugation at 400 × g for 5 min, 
cells were washed and resuspended in PBS and stored on ice until 
flow cytometry was performed. Flow cytometry was performed 
using a BD LSR II benchtop analyzer for flow cytometry. The 
data were gated to calculate the percentage of nucleated cells of 
each marker type in the sample and the following two combina-
tions of markers named MSC1 and MSC2. The first definition 
was CD90+, CD44+, and CD45− (MSC1). This was designed to be 
a broad definition of possible MSCs. The second definition was 
more stringent and included CD90+, CD44+, CD45−, CD14−, and 
CD34− (MSC2).
Fluorescent-activated cell sorting and 
Differentiation
The remaining cells were cultured in T-75 flasks with growth 
medium (DMEM with 10% FBS and 1% PEST) until conflu-
ence. Plastic adherent cells were lifted and sorted using 
fluorescent-activated cell sorting (FACS) to get a viable, 
homogenous population of CD90+, CD44+, and CD45− cells. 
Cells were placed in 50 ml tubes with DNase I solution. Ten 
milliliters of PBS was slowly added dropwise while swirling the 
tube, then centrifuged at 500 × g for 5 min, and the supernatant 
was discarded. The cells were washed and resuspended in 
1  ml PBS with dextrose +  1  mM EDTA. Cells were counted 
using Trypan blue staining. Antibodies for CD90, CD45, and 
CD44 were added to the tubes and incubated. The cells were 
sorted into the defined populations using FACS such that a 
pure population with the appropriate cell marker profile was 
produced.
The cells were plated in six-well plates (1.8 × 104 cells/well) 
and cultured in growth medium until 90% confluence prior 
to differentiation. For chondrogenic differentiation, cells were 
lifted, washed with PBS, and resuspended in DMEM. Four 
conical tubes were seeded with 2 ×  105 cells and centrifuged 
generating a pellet. The supernatant was replaced with growth 
medium (control; n = 2) or chondrogenic medium (treatment; 
n = 2). The chondrogenic medium (10 ng/ml DMEM with high 
glucose, 10  ng/ml TGF-B3, 4  mM l-glutamine, 10−7 M dexa-
methasone, 0.17 mM ascorbic acid, 0.35 mM l-proline, 1 mM 
1 AbD Serotec Raleigh, NC, USA.
2 Lynx Rapid Ab Conjugation Kit, AbD Serotec.
sodium pyruvate, 1% PEST) was changed every 2–3  days for 
3 weeks (24). The pellets were sectioned and stained with Alcian 
Blue for glycosaminoglycan.
For osteogenic differentiation, the medium in two wells was 
replaced with osteogenic medium (DMEM, 10% FBS, 10  mM 
β-glycerophosphate, 10−7 dexamethasone, and 0.05 mM ascorbic 
acid-2-phosphate, 1% PEST) (25). Two additional wells were 
maintained with growth medium as controls. The osteogenic 
medium was changed every 3  days for 3  weeks and the stain-
ing was performed on the cells with Alizarin Red. A subjective 
comparison between control and differentiated samples was used 
to determine positive and negative staining.
statistical analysis
Nucleated cell concentration (nucleated cell/g of tissue or ml of 
blood), total nucleated cell count, and potential MSCs using both 
definitions were calculated for each site and dog. The total number 
of potential MSCs was calculated by multiplying the percentage 
of cells expressing CD90+, CD44+, and CD45− (MSC1) or CD90+, 
CD44+, CD45−, CD14−, and CD34− (MSC2) in the sample by the 
total number of nucleated cells.
Matched pairs t-tests were used to statistically compare sites. 
Variation was compared among sites using a Levine test. Patient 
body condition was also evaluated with respect to MSC numbers 
using regression analysis. Differences were considered significant 
at P < 0.05.
resUlTs
harvest
All 10 dogs were under 2  years of age with a range of 
13–21 months old. The median body condition score was 4.5 
with a range of 3.5–7 out of 9. Patient body weight and body 
condition score were not significantly associated with total cell 
concentration. The mean volume of bone marrow samples col-
lected was 20  ml (range 10.5–27  ml). The mean weight of all 
adipose tissue samples collected was 29 g (range 14–55 g). All 
falciform fat samples were 30 g or higher, but harvesting 30 g of 
subcutaneous fat was not always possible despite extensive dis-
section. The harvest of bone marrow overall was slightly more 
challenging compared to the adipose given the strength and aim 
necessary to get through the cortex and into the marrow. The 
ilium was more difficult than the humerus or tibia. The easiest 
site to harvest was the falciform.
Flow cytometry
The data for each biomarker, site, and tissue harvested are pre-
sented in detail in Tables 1 and 2. Table 1 contains the mean and 
SD of total cells by marker, and Table 2 gives the total nucleated 
cells, the nucleated cell concentration, total potential MSCs for 
each tissue, and the potential MSCs for each tissue as a percent of 
the total nucleated cell count.
The nucleated cell concentrations harvested were significantly 
(P <  0.05) increased in aspirates harvested from the humerus 
when compared to the ilium and tibia. Similarly, the nucleated cell 
concentrations were significantly (P < 0.05) increased in adipose 
FigUre 1 | Total number of Mscs collected at each site (mean ± sD). 
Cells were designated as MSCs based on one of the two definitions: 
definition 1: CD90+, CD44+, and CD45− (A–C); definition 2: CD90+, CD44+, 
CD45−, CD14−, and CD34− (a–d). Different letters above bars indicate 
significant (P < 0.05) differences among sites. In other words, those labeled 
with the same letter are not statistically different. Upper case letters indicate 
differences based on the analyses of three cell markers, whereas lower case 
letters indicate differences between analyses of five cell markers. Graph has 
been log transformed.
TaBle 2 | numbers and concentrations of cells.
site of collection (mean ± sD) 
Msc 1 = cD90+ cD44+ cD45− 
Msc 2 = cD90+ cD44+ cD45− cD14− cD34−
humerus ilium Tibia Falciform sQ shoulder
Total nucleated cell number (×106) 851.63 ± 108.54 966.85 ± 321.89 131.99 ± 55.86 12.60 ± 1.40 4.93 ± 0.91
Nucleated cell concentration (cells × 106/ml  
bone marrow or cells × 105/g adipose)
39.25 ± 4.25 23.10 ± 1.97 4.50 ± 1.00 3.72 ± 0.45 2.10 ± 0.33
Total MSCs MSC 1 (×106) 1366.66 ± 360.59 1348.12 ± 823.05 78.91 ± 27.07 82.86 ± 19.42 25.25 ± 4.16
Total MSCs MSC 2 (×106) 120.90 ± 25.22 584.54 ± 473.64 17.25 ± 7.01 5.10 ± 1.36 0.73 ± 0.19
MSC 1% of nucleated cells 1.50 ± 0.35 1.08 ± 0.24 0.69 ± 0.11 7.71 ± 2.71 5.55 ± 0.84
MSC 2% of nucleated cells 0.13 ± 0.02 0.32 ± 0.15 0.19 ± 0.05 0.44 ± 0.14 0.23 ± 0.09
Mean (±SD) of total nucleated cell number, concentration of nucleated cells, total number of potential mesenchymal stem cells (MSCs), and MSCs based on definition MSC 1 and 
MSC 2 as a percentage of nucleated cells.
TaBle 1 | Mean (±sD) percentage of cells for each marker and site of collection.
site of collection (mean% of cells ± sD)
Marker humerus ilium Tibia Falciform sQ shoulder
CD44+ 26.78 ± 2.64 21.87 ± 3.48 19.35 ± 2.24 49.05 ± 5.24 43.25 ± 3.02
CD14− 66.42 ± 3.00 69.37 ± 4.07 73.25 ± 2.91 55.78 ± 4.43 54.50 ± 2.15
CD90+ 25.21 ± 2.41 25.17 ± 2.21 21.69 ± 2.11 31.75 ± 3.23 36.28 ± 3.22
CD166+ 51.55 ± 1.78 49.43 ± 3.38 51.50 ± 2.93 32.76 ± 3.67 47.74 ± 3.91
CD45− 63.13 ± 3.18 61.97 ± 6.83 70.42 ± 3.27 68.43 ± 2.10 62.63 ± 2.75
CD34− 61.13 ± 1.96 61.97 ± 2.95 2.93 ± 2.39 48.08 ± 2.12 32.02 ± 6.28
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tissue harvested from the falciform ligament when compared 
to the caudal scapular region. The total nucleated cell counts 
obtained from the humerus and the ilium were significantly 
higher (P < 0.05) when compared to the total cell numbers har-
vested from the tibia, falciform ligament, and the caudal scapular 
subcutaneous region (Figure 1, Table 2).
The potential MSC concentration from the falciform and 
subcutaneous shoulder adipose was significantly higher 
(P < 0.05) when compared to the humerus, ilium, and tibia using 
cell surface markers CD90+, CD44+, and CD45− (Figure  2). 
However, the total number of potential MSCs isolated from the 
humerus was significantly (P <  0.05) higher when comparing 
those isolated from the tibia, falciform ligament, and the caudal 
scapular subcutaneous region using cell surface markers CD90+, 
CD44+, and CD45− (Figure 1). When using the more stringent 
MSC definition, the pattern remained similar for each site but 
statistical differences were not always significant. Variation was 
limited in the adipose tissue samples compared to bone marrow 
(P < 0.05).
Facs and Differentiation
A homogenous population of CD90+, CD44+, and CD45− cells 
adhered to plastic and proliferated to 90% confluence. Subjective 
evaluation of the cells treated with osteogenic media showed 
positive Alizarin Red staining over the cells subjected to growth 
media. The pelleted cells subjected to chondrogenic media 
showed subjectively greater glycosaminoglycan deposition than 
control pellets as stained by Alcian Blue (Figures 3 and 4). No 
other testing was performed to further elucidate or quantify dif-
ferentiation efficiency or character.
DiscUssiOn
harvest
Clinically, the technical difficulty of the harvest is very important. 
It is arguable which tissue harvest is more invasive. All methods of 
FigUre 3 | histological images showing osteogenic differentiation of 
cells. Adipose tissue (a–D) or bone marrow (e–h) stained with Alizarin Red 
for calcium at two magnifications. Control aMSCs [(a) 4×; (B) 20×] or 
differentiated aMSCs in osteogenic medium [(c) 4×; (D) 20×]. Control 
bMSCs [(e) 4×; (F) 20×] or differentiated bMSCs in osteogenic medium [(g) 
4×; (h) 20×].
FigUre 2 | Percentage of Mscs from each extraction site 
(mean ± sD). Cells were designated as MSCs based on one of the two 
definitions: definition 1: CD90+, CD44+, and CD45− (A–C); definition 2: 
CD90+, CD44+, CD45−, CD14−, and CD34− (a–d). Different letters above bars 
indicate significant (P < 0.05) differences among sites. In other words, those 
labeled with the same letter are not statistically different. Upper case letters 
indicate differences based on the analyses of three cell markers, whereas 
lower case letters indicate differences between analyses of five cell markers. 
Graph has been log transformed.
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harvest had some degree of morbidity. Harvesting bone marrow 
was technically more difficult than harvesting adipose tissue, 
which is consistent with our first hypothesis. For adipose tis-
sue collection, the caudal scapular subcutaneous tissue region 
required more dissection and did not yield as much tissue as the 
falciform fat region. This was likely related to the generally low 
body condition of the dogs. Clinical populations of dogs may 
have higher body condition scores and thus more subcutaneous 
adipose deposits. Other sites may yield different or better results 
(i.e., inguinal fat) (26, 27). Among the bone marrow sites, the 
humerus was subjectively the easiest site to sample, followed by 
the tibia, and the ilium was the most difficult site for bone marrow 
harvesting.
Human adipose tissue is more readily abundant and accessible 
than human bone marrow (28). Our results may differ due to a 
lower ratio of fat to muscle in the population of canines used when 
compared to humans. The great abundance and ease of adipose 
tissue harvest in humans, where samples are commonly obtained 
in liters after liposuction, are far greater than in dogs where 30 g 
may be difficult to obtain (2). Interestingly, in this study, body 
condition was not related to the total number of potential MSCs 
in adipose tissue. This is likely due to the limited range of body 
condition in the study population.
characterization of cell Populations
Ideally, the content of a solution advocated for the treatment of 
any disease would be known with the least amount of variation 
possible. SVF has been advocated for several diseases in dogs, but 
the content of the SVF has been extrapolated from other species. 
This study describes a step in defining the SVF in dogs. Similar 
to humans, our research shows that adipose tissue has a higher 
percentage of potential MSCs (as defined by the biomarkers used) 
than bone marrow (2, 16). However, we must reject our second 
hypothesis as bone marrow had a higher total nucleated cell count 
than adipose tissue. This is likely because of the numbers of white 
blood cells expected in bone marrow but absent in adipose tissue.
Even with a higher concentration of potential MSCs in the 
SVF, there are still 92.3% of cells that are undefined in dogs and 
injected into joints or tissues. In humans, SVF is made up of 
white blood cells (25–45%), endothelial cells (10–20%), pericytes 
(3–5%), and stromal cells (15–30%) (4).
No individual site was best for all outcomes assessed (i.e., total 
number of nucleated cells, total number of potential MSCs, cells/
tissue collected, variability, etc.). The best site varied depending 
upon which outcome was assessed. For instance, the tibia yielded 
lower total number of potential MSCs, but it was also the most 
FigUre 4 | histological images showing chondrogenic differentiation. 
Adipose tissue (a–D) or bone marrow (e–F) at two magnifications stained for 
glycosaminoglycans with Alcian Blue. Control aMSCs [(a) 4×; (B) 20×] or 
differentiated aMSCs in chondrogenic medium [(c) 4×; (D) 20×]. Control 
bMSCs [(e) 4×; (F) 20×] or differentiated bMSCs in chondrogenic medium 
[(g) 4×; (h) 20×].
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consistent. Fat from the falciform ligament contained a greater 
concentration of cells defined as MSC1, which is consistent with 
our third hypothesis. However, bone marrow-derived potential 
MSC1 cells were harvested in greater total number. This makes 
determining the best location for stem cell harvest difficult. Some 
outcomes are more important than others depending on the 
potential use of the MSCs. SVF injected into a joint or tendon 
would ideally have high number of MSCs and a low number of 
other nucleated cells (high percentage of MSCs), assuming that 
the remaining nucleated cell population is not therapeutic and 
that the minimum number of MSCs required is present. However, 
if the SVF was going into culture, the highest total starting num-
ber is arguably more important.
Cell yields vary between collection sites and species (18, 21, 
29–31). Specifically in dogs, Neupane et al. found that inguinal 
fat had a low number of cells per gram of fat, and that cells did 
not proliferate well after adhering to plastic (18). Subcutaneous 
fat appeared most promising, followed by omental fat (18). Even 
though the study presented here and Neupane calculated the 
concentration of MSCs harvested from subcutaneous fat, the 
flow cytometery was performed on adherent cells rather than 
the SVF (18). This eliminated non-adherent cell populations, 
preventing direct comparison between studies. Perhaps more 
importantly, some studies address the differences between sites 
with regard to differentiation postharvest (30, 32). The ability 
to differentiate was assessed in this study, but the efficiency or 
quality of differentiation was not compared among the sites or 
tissues. These cell populations and their markers may be dif-
ferent from the SVF that is currently being injected back into 
patients (8, 16).
The data in this study must be evaluated in light of the 
limitations. There is no definitive set of markers defining MSCs 
for the dog in either cultured MSCs or the SVF (6, 15). Some 
studies report clear differences among various species with 
respect to expression of markers (3, 33, 34). In this study, the 
markers chosen were identified based on consistency across 
other species and known reactivity of the antibodies to canine 
cells. Thus, it is possible that other markers would provide 
a more definitive profile of canine MSCs. However, a recent 
study evaluated canine MSCs derived from bone marrow, 
adipose tissue, muscle, and periosteum with similar markers, 
documenting expression of CD44 and 90 but not of 34 and 45 
(35). Bourin et  al. proposed a set of markers to standardize 
the evaluation of SVF for humans, including CD90+, CD44+, 
CD73+, CD13+, CD29+, CD105+, CD45−, CD235−, CD31−, and 
CD34+ (4). The MSC1 definition used in this article completely 
overlaps but is broader than that proposed characterization. 
Based on these criteria, it can be argued that we included 
populations of cells other than MSCs in our comparison. Using 
the MSC2 definition, which was more stringent and CD34− (in 
contrast to Bourin et al.), the number of MSCs was low. It is 
possible that dogs have less concentrated MSC populations or 
that different markers are needed for this species. The presence 
or absence of CD34 as a marker for MSCs is controversial in 
dogs and is affected by the harvest technique and amount of 
hemorrhage (4, 6, 15). The amount of hemorrhage was not 
specifically quantified in these dogs, although the surgical 
technique was standardized. Ideally, we would have tested all 
known markers for MSCs and the subsequent differentiation to 
develop an ideal canine formula, which may even have varied 
between bone marrow and adipose tissue. This would not be 
practical given the anticanine antibodies and fluorochromes 
available at the time.
The label of MSC has been assigned based on different 
criteria in the literature from the simple (i.e., adherence of cells 
to plastic) to the more robust (i.e., specific marker profiles, pro-
liferation rates, and differentiation into fat, cartilage, bone, and 
more) (5, 9, 10, 30, 36–41). This study presents some evidence 
of differentiation, but it is not as robust as would be argued 
by Dominici et al. For instance, Dominici et al. proposed that 
differentiation into adipose tissue was necessary to determine 
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the differentiation potential of MSCs (5). Additionally, further 
characterization of the tissue by PCR, immunohistochem-
istry, or other biochemical techniques would have provided 
additional evidence of differentiation rather than the staining 
techniques used here. Using this definition, we could not call 
the cells in this study MSCs. However, if the simplest defini-
tion in the literature (plastic adherent cells) is used, the cells 
isolated with the given markers would be considered MSCs 
despite the chance that some of the sorted cells are progeni-
tor cells rather than MSCs (9, 10, 30, 32, 36–40). Most studies 
assessing the biomarker profile of MSCs use adherent cells for 
differentiation rather than a specific population of cells sorted 
for the biomarker profile. Although differentiation is tested in 
these studies, a mixed population of cells is often used, mak-
ing it difficult to establish differentiation of the cells with the 
phenotype presented or the remaining population of cells (1, 
2, 7, 10, 16, 18, 20, 25, 28, 32, 38, 40). Progenitor cells may be 
part of the population driving some of the differentiation. Using 
the second more stringent definition of MSC (MSC2) may be 
eliminating progenitor cells.
Vieira et al. also performed extensive outcome measures for 
differentiation of cultured canine MSCs including flow cytom-
etry, proliferation of plastic adherent cells, histopathologic stain-
ing, and PCR (42). Although the differentiation data are weak 
in this study, the markers used are consistent with those shown 
and differentiated by Vieira et  al. (42). The aMSCs from dogs 
were characterized by flow cytometry for the expression of 10 
cell surface proteins (CD13, CD29, CD31, CD34, CD44, CD45, 
CD73, CD90, CD105, and CD117). At passage 4, the majority of 
adipose derived stem cells (cASCs) expressed CD44, CD29 (β1 
integrin), and CD90 (Thy1) adhesion molecules. Other markers, 
including CD14, CD34, CD45, and CD117, were consistently 
absent in few cells (42). This shows that the expression charac-
teristics change or the cell population changes in plastic adherent 
cells, thus injecting plastic adherent cells into a joint or tendon 
may be different than injecting the SVF.
The SVFs were frozen before flow cytometry in our study. 
This may have affected the expression of cell surface markers 
or the viability of the cells. However, one study showed that the 
proliferation and differentiation capacity as well as the cellular 
characteristics were identical in freshly derived bone marrow-
derived stem cells (bMSCs) and bMSCs derived after freezing 
and storage (43).
The variation in our data among dogs was large. This degree of 
variation is consistent with previous studies in other species (34). 
MSC cell yield had also been shown to be quite variable among 
patients in several studies and may be affected by several factors, 
including harvesting site or method (38). The volume obtained 
while harvesting the marrow was variable despite the use of a 
standardized needle and syringe for all sites. It is possible that 
when a large volume was obtained, the sample was hemodiluted 
adding to the variability of the bone marrow samples. One reason 
for very small samples may have been random needle occlusion 
either by clot or tissue. This information was not recorded at the 
time of harvest.
Age and weight may also contribute to variation. One study 
showed that attachment and proliferation capacity are more pro-
nounced in aMSCs derived from younger donors compared with 
older donors (44, 45). The dogs in this study were all skeletally 
mature, but they were also young (<2 years). Therefore, results in 
older dogs may differ. This is substantiated by a study reporting 
decreasing nucleated cells in the SVF derived from adipose in 
successive age groups (26).
Although a correlation with body condition was not found in 
this study, it is possible that more aMSCs could be procured from 
canine subjects with greater body condition scores. This study 
did not include obese dogs. The mean body condition score of 
dogs sampled in this study was 4.5, which is quite lean. However, 
one human study showed that the ratio of adipocytes to MSCs 
is constant in humans, independent of body mass index and 
age (46). This allows a greater harvest of MSCs from patients or 
subjects with a higher BMI.
Based on the surgical and in  vitro data presented, fat from 
the falciform ligament appears to be the logical choice to harvest 
tissue, if the SVF is going to be injected back into the injury 
site. Although bone marrow yielded the greatest total number 
of CD90+, CD44+, and CD45− cells, the falciform ligament was 
the easiest to harvest, provided the most consistent yield, and 
possessed the highest ratio of CD90+, CD44+, and CD45− cells to 
other nucleated cells. This research may be used as a foundation 
for future research and development of cell-based therapies in 
the dog.
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